Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-2570 in Non-Segmental Vitiligo
NCT07625891Phase 2Recruiting
- Sponsor
- InventisBio
- Start
- Jun 2026
- Primary completion
- Nov 2027
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of D-2570 in Vitiligo (4 arms), sponsored by InventisBio. Primary endpoint: Percentage change from baseline in Facial Vitiligo Area Scoring Index at 24 weeks. Started Jun 2026; status: recruiting.
02
Drugs
D-2570
03
Conditions
Vitiligo
Beyond the preview
Go deeper on NCT07625891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07625891.